- <![CDATA[FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma]]><![CDATA[Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.]]>onclive · 2mo ago↗ source
- <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC ]]><![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.]]>onclive · 2mo ago↗ source
- <![CDATA[FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma ]]><![CDATA[The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma. ]]>